Navigation Links
Watson Announces Preliminary Financial Performance for FY 2010
Date:1/12/2011

SAN FRANCISCO, Jan. 12, 2011 /PRNewswire/ -- At the 29th Annual J.P. Morgan Healthcare Conference, Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that based on a preliminary review of 2010 results, it expects net revenues to increase more than 25 percent to more than $3.5 billion compared to 2009. Adjusted cash earnings per share is expected to be at or slightly above the midpoint of the company's latest forecast of $3.37 to $3.45 per share, a greater than 12 percent increase over 2009.  This is based on a preliminary review of the Company's operating results for the fourth quarter and year-ended December 31, 2010.

"2010 was another year of exceptional performance," said Paul Bisaro, CEO of Watson Pharmaceuticals.  "We experienced continued solid growth across the business with particularly strong contributions from our generic extended-release and oral contraceptive franchises in the U.S., as well as from our Anda distribution business. Strong cash flows allowed us to repay over $450 million of short term debt during 2010, eliminating our 2011 debt obligations.  We are looking forward to the planned 2011 U.S. launches of generic versions of Concerta® and Lipitor® which will support our continued revenue and earnings performance."

Watson's preliminary results remain subject to finalization by its management and review by its outside independent accountants.  The company plans to report final results for the fourth quarter and full year 2010 on February 15, 2011.

Watson will provide an update of its business and will provide an outlook for 2011 at an Investor Day to be held in New York City on Friday, January 21, 2010 at 8:30 a.m. eastern time.  The January 21st analyst meeting will be webcast live, and can be accessed by logging onto http://www.watson.com or the following link: '/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson to Host Investor Day on January 21 in New York City
2. Watsons Generic Fentora® Receives FDA Approval
3. Watson to Present at the 29th Annual JP Morgan Healthcare Conference
4. Watson Announces Novel Oral Contraceptive Approval
5. Watson and Richter Announce Exclusive License Agreement for Esmya™
6. Watson Confirms Exalgo™ Patent Challenge
7. Watson Announces Pricing of Secondary Offering By Selling Stockholder
8. Watson Announces Commencement of Secondary Offering by Selling Stockholder
9. Watson To Present At The 2010 Credit Suisse Healthcare Conference
10. Watson Confirms Crestor® Patent Challenge
11. Watsons Generic Version of Lotrel ® Receives FDA Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/28/2015)... The global mHealth market ... by 2020, growing at a CAGR of 47.6% from ... Grand View Research, Inc. Monitoring services is expected to ... to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... incidences of chronic diseases such as cancer, heart ailments, ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation ... scheduled to present at three upcoming healthcare conferences.  ... and CEO, will present at the Rodman & Renshaw ... Eastern time. The conference is being held at the ... . A live audio webcast of the presentation ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... 2012   Hospira, Inc. (NYSE: HSP ), ... today announced enrollment of the first patient in a Phase ... Phase III program, which follows a successful Phase I trial ... Hospira,s EPO and the reference product, Amgen,s Epogen ® ...
... LUTHERVILLE, Md., Jan. 9, 2012  The National ... nonprofit organization that facilitates cooperation between law ... pharmaceutical manufacturers in the prevention and investigation ... the National Precursor Log Exchange (NPLEx) in ...
Cached Medicine Technology:Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 3Kentucky Real-Time, Stop-Sale System Is Effective In Blocking Illegal Sales Of Pseudoephedrine 2
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... On Saturday, ... Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program titled ... 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... Dr. ... a mission. His mission is to increase acceptance of the chiropractic field in ... medications that further debilitate them. Although Chiropractic was made available to the VA ...
(Date:8/29/2015)... ... August 29, 2015 , ... People ... pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire smoke ... attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine educational ... as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator ... third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... for human malignant mesothelioma (MM) that will provide valuable ... directions for design of therapeutic strategies. The research, published ... Cell, may eventually lead to a substantially improved outlook ... is an aggressive cancer originating from the mesothelial lining ...
... who do not comply with treatment instructions for osteoporosis ... likely to suffer further fractures, which seriously affects their ... to provide support to these patients and address their ... guidelines drawn up, according to lead researcher Professor Cyrus ...
... University Medical Center say they may have figured out ... in women than in men. , Their study, appearing ... that poor sleep is associated with greater psychological distress ... of heart disease and type 2 diabetes. They ...
... VALLEY, Calif., March 10 VoIP-PAL.com,Inc. (Pink Sheets: ... pleased to report it has chosen the Carol ... first recipient. Four,dollars from each transaction exclusively through ... VoIP-PAL.com,s clients will additionally have the option to ...
... should be left on, then removed as a unit once ... During on-field treatment of young athletes with suspected neck injuries, ... initial stabilization and transport, and removed when the patient is ... "There was a clear hole in the on-the-field guidelines in ...
... making many diseases increasingly difficult--and sometimes impossible--to treat, ... the National Institute of Allergy and Infectious Diseases ... Extensively drug-resistant tuberculosis and invasive methicillin-resistant Staphylococcus aureus ... this problem that pose serious threats to domestic ...
Cached Medicine News:Health News:Mouse model for mesothelioma reproduces human disease 2Health News:Make or break time for osteoporosis treatment 2Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:VoIP-PAL.com, Inc. (Pink Sheets: VPLM.PK - News) UPDATE: Announces First Award Recipient of TalkfortheCure(TM) Dollars 2Health News:New Guidelines Urged for Young Athletes' Neck Injuries 2Health News:Confronting the challenge of antimicrobial resistance 2Health News:Confronting the challenge of antimicrobial resistance 3
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... our High Penetration Steered Linear Peripheral Vascular ... to 8 MHz. It is our ... Detection with 4 different settings to optimize ... The high color and Doppler sensitivity of ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: